Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.54 |
| ▸ | GABRD | O14764 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.54 |
| ▸ | GABRE | P78334 | 2/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GPR3 | P46089 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178553 | 1.00 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL23580301 | 0.77 | CHUK (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19409374 | 0.75 | HPGD (0.46) | ALDH1A1GPR3HSD17B10AHRLMNA | |
| SCHEMBL674512 | 0.74 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29883573 | 0.74 | CA5A (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL675082 | 0.72 | CA5A (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10642293 | 0.70 | GABRP (1.00) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL24461482 | 0.70 | SMARCA2 (0.44) | ALDH1A1GPR3HSD17B10AHRCA5A | |
| SCHEMBL79405 | 0.69 | ALDH1A1 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31285932 | 0.69 | GABRP (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569485-B2 | SMARCA inhibitors and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4363425-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133917-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GABRP 4347/4885GABRD 3327/4885GABRA1 3632/4885 |
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | GABRP 4100/4885GABRD 4101/4885GABRA1 3965/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | GABRP 4347/4885GABRD 3327/4885GABRA1 3632/4885 |
| US-12569485-B2 | SMARCA inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA2 | GABRP 3560/4885GABRD 3635/4885GABRA1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.